SYK vs ZBH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ZBH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SYK and ZBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SYK and ZBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.

Full SYK guide

Zimmer Biomet Holdings, based in Warsaw, Indiana, makes the hardware that goes inside roughly a million joint replacement patients a year. Its reporting lines are knees, hips, S.E.T. (sports medicine, extremities and trauma), and craniomaxillofacial and thoracic, with a separate technology and data line covering the ROSA robotic platform, navigation and mixed-reality software. Trailing twelve-month revenue runs about ~$8.51B across roughly 17,000 employees. Two acquisitions reshaped the mix recently: Paragon 28 for about ~$1.2B, which added a dedicated foot and ankle franchise, and Monogram Technologies for about ~$177M in equity value (~$4.04 per share, closed in 2025), which brought semi-autonomous and autonomous robotic capability alongside the existing ROSA installed base of nearly 2,000 systems.

Full ZBH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• SYK drivers: Mako robotics and enabling technology; MedSurg and Neurotechnology breadth.
• ZBH drivers: Hips and technology are carrying the growth, not knees; ROSA is a placement business, not a robot business.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple. For ZBH, the most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file).

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SYK if you believe its drivers more; ZBH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SYK and ZBH guides.

SYK. Stryker trades around $330 per share with a market cap near $127 billion, a premium franchise multiple that reflects its consistent growth record. Trailing P/E has run in the high-30s while the forward P/E sits closer to 22x on expected earnings growth. The Q1 2026 cyber incident dented near-term results, but management reaffirmed full-year organic growth guidance of 8.0% to 9.5%.

ZBH. At a market capitalization near ~$18.97B, Zimmer Biomet is valued at roughly 2.2x trailing sales and about ~11x to ~12x guided 2026 adjusted earnings. Stryker trades near ~20.6x forward earnings and Johnson & Johnson near ~23.5x, so the gap is not marginal, it is close to half. What the multiple is arguing about is durability of growth rather than current profitability: adjusted operating margin near ~25.7% is still healthy, but it is heading down this year while the reported organic growth rate sits in the low single digits.

Headline figures (approximate, July 2026): SYK shows revenue (2025) ~$25.1B, q1 2026 revenue ~$6.0B (+2.6% YoY), 2026 adj. eps guidance ~$14.90-$15.10, market cap ~$127B; ZBH shows revenue (ttm) ~$8.51B, q2 2026 net sales ~$2.18B, up ~4.8% reported and ~4% organic constant currency, 2026 adjusted eps guidance ~$8.47 to ~$8.59 (raised), forward p/e ~11.7x guidance midpoint at ~$99 per share.

SYK and ZBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SYK and ZBH exposure against your real portfolio. It is not an investment adviser.